Abbvie (ABBV) and Johnson & Johnson (JNJ) Poised for Immunology Upside - JPMorgan
Tweet Send to a Friend
JPMorgan analyst Chris Schott reiterated a $135.00 price target on Abbvie (NYSE: ABBV) and a $175 price target on Johnson ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
